Page last updated: 2024-10-17

bupropion and Suicidal Ideation

bupropion has been researched along with Suicidal Ideation in 13 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Suicidal Ideation: A risk factor for suicide attempts and completions, it is the most common of all suicidal behavior, but only a minority of ideators engage in overt self-harm.

Research Excerpts

ExcerptRelevanceReference
" This study explored whether anxiety predicts suicidal ideation in depressed individuals treated with paroxetine or bupropion."9.27Effects of anxiety on suicidal ideation: exploratory analysis of a paroxetine versus bupropion randomized trial. ( Burke, AK; Chaudhury, SR; Ellis, SP; Grunebaum, MF; Keilp, JG; Mann, JJ; Marver, JE; Metts, AV; Oquendo, MA; Parris, MS, 2018)
"The authors reanalyzed data from the 17 placebo-controlled randomized controlled trials (N=8,027) of varenicline conducted by Pfizer, using complete intent-to-treat person-level longitudinal data to assess smoking abstinence and reports of suicidal thoughts and behavior, depression, aggression/agitation, and nausea and to compare effects in patients with (N=1,004) and without (N=7,023) psychiatric disorders."7.79Varenicline, smoking cessation, and neuropsychiatric adverse events. ( Gibbons, RD; Mann, JJ, 2013)
"This report used acute treatment data from a clinically representative sample of outpatients with nonpsychotic major depressive disorder (N = 665) participating in the Combining Medications to Enhance Depression Outcomes trial, who received up to 12 weeks of escitalopram, escitalopram plus bupropion SR, or venlafaxine XR plus mirtazapine."5.30The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. ( Carmody, TJ; De La Garza, N; Grannemann, BD; Killian, MO; Rush, AJ; Trivedi, MH, 2019)
"In a randomized clinical trial comparing paroxetine and bupropion for treatment of depression in patients with either suicidal ideation or past attempt, depression severity and suicidal ideation were assessed weekly during the 8-week study."5.27Suicidal ideation declines with improvement in the subjective symptoms of major depression. ( Burke, AK; Ellis, SP; Gorlyn, M; Grunebaum, MF; Keilp, JG; Mann, JJ; Oquendo, MA, 2018)
" This study explored whether anxiety predicts suicidal ideation in depressed individuals treated with paroxetine or bupropion."5.27Effects of anxiety on suicidal ideation: exploratory analysis of a paroxetine versus bupropion randomized trial. ( Burke, AK; Chaudhury, SR; Ellis, SP; Grunebaum, MF; Keilp, JG; Mann, JJ; Marver, JE; Metts, AV; Oquendo, MA; Parris, MS, 2018)
" We conducted a double-blind, randomized, clinical pilot trial of paroxetine (N=36) or bupropion (N=38) in DSM IV major depression with a suicide attempt history or current suicidal ideation."5.16Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression. ( Burke, AK; Duan, N; Ellis, SP; Grunebaum, MF; John Mann, J; Oquendo, MA, 2012)
"The authors reanalyzed data from the 17 placebo-controlled randomized controlled trials (N=8,027) of varenicline conducted by Pfizer, using complete intent-to-treat person-level longitudinal data to assess smoking abstinence and reports of suicidal thoughts and behavior, depression, aggression/agitation, and nausea and to compare effects in patients with (N=1,004) and without (N=7,023) psychiatric disorders."3.79Varenicline, smoking cessation, and neuropsychiatric adverse events. ( Gibbons, RD; Mann, JJ, 2013)
"Reduced suicidal ideation was best predicted by a combination of the independent improvements in both depression symptomatology and verbal memory."2.80Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropion. ( Burke, A; Gorlyn, M; Grunebaum, M; Keilp, J; Mann, JJ; Oquendo, M, 2015)
"Prior studies have suggested that major depressive disorder (MDD) with pre-adult onset represents a distinct subtype with greater symptom severity and higher rates of suicidal ideation."2.78Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. ( Balasubramani, GK; Kurian, B; Rush, AJ; Sung, SC; Trivedi, MH; Warden, D; Wisniewski, SR; Zisook, S, 2013)
"Baseline suicidal ideation was associated with greater depressive severity, childhood neglect, childhood abuse, early major depressive disorder onset, greater psychiatric comorbidity, and worse functioning and quality of life."2.76Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. ( Fava, M; Kallenberg, G; Lebowitz, B; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2011)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's12 (92.31)24.3611
2020's1 (7.69)2.80

Authors

AuthorsStudies
Weissman, CR1
Hadas, I1
Yu, D1
Jones, B1
Kong, D1
Mulsant, BH1
Blumberger, DM1
Daskalakis, ZJ2
Keilp, JG3
Ellis, SP4
Gorlyn, M2
Burke, AK4
Oquendo, MA4
Mann, JJ5
Grunebaum, MF4
Parris, MS1
Marver, JE1
Chaudhury, SR1
Metts, AV1
Lewis, CP1
Camsari, DD1
Sonmez, AI1
Nandakumar, AL1
Gresbrink, MA1
Croarkin, PE1
De La Garza, N1
Rush, AJ3
Killian, MO1
Grannemann, BD1
Carmody, TJ1
Trivedi, MH3
Gibbons, RD1
Sudol, K1
Bauer, N1
Keilp, J1
Burke, A1
Oquendo, M1
Grunebaum, M1
Duan, N1
John Mann, J1
Zisook, S2
Lesser, IM1
Lebowitz, B1
Kallenberg, G1
Wisniewski, SR2
Nierenberg, AA1
Fava, M2
Luther, JF1
Morris, DW1
Perlis, RH1
Uher, R1
Perroud, N1
Sung, SC1
Balasubramani, GK1
Kurian, B1
Warden, D1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Controlled Trial of Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation Associated With Major Depressive Disorder[NCT04502758]80 participants (Anticipated)Interventional2022-04-04Recruiting
Combining Medications to Enhance Depression Outcomes[NCT00590863]Phase 4665 participants (Actual)Interventional2008-03-31Completed
Paroxetine Versus Bupropion for Suicide Ideators or Attempters With Major Depressive Disorder[NCT00429169]Phase 4101 participants (Actual)Interventional2004-06-30Terminated (stopped due to Interim analysis showed differential treatment effects.)
SSRI Versus Bupropion in High-Risk Major Depressive Disorder[NCT01748955]Phase 415 participants (Actual)Interventional2010-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Quality of Life Inventory

The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7

Interventionunits on a scale (Mean)
Escitalopram + Bupropion SR0.6
Venlafaxine XR + Mirtazapine0.4
Escitalopram + Placebo0.4

Quick Inventory of Depressive Symptoms

Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7

Interventionpercentage of participants (Number)
Escitalopram + Bupropion SR46.6
Venlafaxine XR + Mirtazapine41.8
Escitalopram + Placebo46.0

Brain Activity Measured by BOLD Signal With fMRI During a Reward Processing Task.

"Comparison of fMRI results at baseline and after 8 weeks of antidepressant pharmacotherapy with paroxetine vs. bupropion.~Percent change in contrast of parameter estimates (COPE). COPE is measured during Monetary Incentive Delay Task.~Task conditions are:~Reward=BOLD signal when subject wins 5 cents vs. wins 0 cents Punishment=BOLD signal when subject loses 5 cents vs. loses 0 cents" (NCT00429169)
Timeframe: Baseline and Week 8.

Interventionpercentage of change in COPE (Mean)
Paroxetine-0.27
Bupropion-0.95

Go-No go Test

Change in neuropsychological measure of impulsivity. Computer-based task involving induction of a dominant response tendency and testing of the subject's ability to withhold responding to less frequent non-target stimuli. (NCT00429169)
Timeframe: Measured at Baseline and Week 8

InterventionCommission errors (Mean)
Paroxetine-0.09
Bupropion-0.06

Occurrence of Suicidal Ideation or Acts Necessitating a Change in Treatment

Suicide attempts, other suicidal behavior, or increase in suicidal thoughts that required a change in clinical treatment. (NCT00429169)
Timeframe: Measured at Month 6

InterventionEvents (Number)
Paroxetine4
Bupropion6

Scale for Suicidal Ideation

The clinician-rated Beck Scale for Suicidal Ideation (SSI) (Beck et al 1979)was used weekly for 8 weeks. It has 19 items scaled 0 (least severe) to 2 (most severe) and total score is the sum, ranging 0 to 38 (Beck et al 1979). Items measure frequency, intensity, and attitudes toward suicidal thoughts, feelings of control over them, and suicide plans. Mean score in 90 inpatients hospitalized for suicidal ideation was 9.4±8.4, versus 4.4±5.8 in outpatients as cited in the study by Beck et al, 1979. (NCT00429169)
Timeframe: Baseline and Week 8

,
InterventionPoints on Scale for Suicidal Ideation (Mean)
BaselineWeek 8
Bupropion9.94.7
Paroxetine8.02.3

Change in Suicidal Ideation (SSI Score)

Beck Scale of Suicidal Ideation Minimum Value = 0 Maximum Value = 38 Higher score is more severe suicidal thoughts (NCT01748955)
Timeframe: Measured at Baseline and Week 8

,
Interventionunits on a scale (Mean)
BaselineWeek 8
Bupropion113.3
Paroxetine CR4.80.3

Percent Change in Contrast of Parameter Estimates (COPE)

"% change in COPE = (Post-treatment COPE - Pre-treatment COPE) / Pre-treatment COPE COPE is measured during Monetary Incentive Delay Task.~Task conditions are:~Reward= BOLD signal when subject wins 5 cents vs. wins 0 cents Punishment= BOLD signal when subject loses 5cents vs. loses 0 cents" (NCT01748955)
Timeframe: Measured at Baseline (pre-treatment) and Week 8 (post-treatment)

,
InterventionPercentage change (Mean)
ACC RewardACC PunishmentAmygdala RewardAmygdala Punishment
Bupropion0.29-1.19-0.90-0.32
Paroxetine CR-2.12-1.33-0.87-0.66

Trials

8 trials available for bupropion and Suicidal Ideation

ArticleYear
Suicidal ideation declines with improvement in the subjective symptoms of major depression.
    Journal of affective disorders, 2018, Volume: 227

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Female; Huma

2018
Effects of anxiety on suicidal ideation: exploratory analysis of a paroxetine versus bupropion randomized trial.
    International clinical psychopharmacology, 2018, Volume: 33, Issue:5

    Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Delayed-Action Preparations; De

2018
The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation.
    Depression and anxiety, 2019, Volume: 36, Issue:4

    Topics: Adult; Aged; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Drug Therapy, Combinatio

2019
SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trial.
    The Journal of clinical psychiatry, 2013, Volume: 74, Issue:9

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depre

2013
Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropion.
    Psychiatry research, 2015, Feb-28, Volume: 225, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cognition Disorders; Depressive Disorder

2015
Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012, Volume: 37, Issue:3

    Topics: Adolescent; Adult; Affect; Aged; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors;

2012
Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012, Volume: 37, Issue:3

    Topics: Adolescent; Adult; Affect; Aged; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors;

2012
Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012, Volume: 37, Issue:3

    Topics: Adolescent; Adult; Affect; Aged; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors;

2012
Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012, Volume: 37, Issue:3

    Topics: Adolescent; Adult; Affect; Aged; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors;

2012
Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
    The Journal of clinical psychiatry, 2011, Volume: 72, Issue:10

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Citalopram; Cyclohexanols; Delayed-Action

2011
Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
    Psychological medicine, 2013, Volume: 43, Issue:5

    Topics: Adolescent; Adult; Age of Onset; Aged; Antidepressive Agents, Second-Generation; Bupropion; Child Ab

2013

Other Studies

5 other studies available for bupropion and Suicidal Ideation

ArticleYear
Predictors of change in suicidal ideation across treatment phases of major depressive disorder: analysis of the STAR*D data.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2021, Volume: 46, Issue:7

    Topics: Antidepressive Agents; Bupropion; Depressive Disorder, Major; Depressive Disorder, Treatment-Resista

2021
Preliminary evidence of an association between increased cortical inhibition and reduced suicidal ideation in adolescents treated for major depression.
    Journal of affective disorders, 2019, 02-01, Volume: 244

    Topics: Adolescent; Adolescent Behavior; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; De

2019
Varenicline, smoking cessation, and neuropsychiatric adverse events.
    The American journal of psychiatry, 2013, Volume: 170, Issue:12

    Topics: Adult; Aggression; Akathisia, Drug-Induced; Benzazepines; Bupropion; Depression; Female; Humans; Mal

2013
New obesity pill: new hopes, old fears.
    Lancet (London, England), 2010, Dec-18, Volume: 376, Issue:9758

    Topics: Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Bupropion; Cardiovascular Diseases; D

2010
Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial?
    The Journal of clinical psychiatry, 2012, Volume: 73, Issue:11

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Buspirone; Citalopram; Cognitive Behavio

2012